A comparative study to assess the efficacy and cost-effectiveness of amisulpride versus olanzapine in schizophrenia patients at psychiatry outpatient department

Chandrashekar Huded; Harish G Bagewadi; Prabhukiran Gogi; Supriya Yedve

doi:10.5455/njppp.2024.14.10482202326042024

2025, Vol: 15, Issue: 5

15 / 5Current Issue Online First Archive Aims and Scope Abstracting & Indexing Most Accessed Articles Most Downloaded Articles Most Cited Articles

Required files to be uploaded

NJPPP Manuscript Submission Form

« Previous Article

Original Research
Online Published: 05 May 2024

Natl J Physiol Pharm Pharmacol. 2024; 14(9): 1971-1975

doi: 10.5455/njppp.2024.14.10482202326042024

A comparative study to assess the efficacy and cost-effectiveness of amisulpride versus olanzapine in schizophrenia patients at psychiatry outpatient department

Chandrashekar Huded, Harish G Bagewadi, Prabhukiran Gogi, Supriya Yedve.

Abstract
Background: Among psychiatric illnesses, schizophrenia remains a chronic debilitating disorder. Although newer atypical antipsychotics have shown better improvement in schizophrenia patients, they are still lacking conclusive evidence-based studies.

Aims and Objectives: The comparative evaluation of amisulpride versus olanzapine in terms of therapeutic efficacy and their cost in schizophrenia patients.

Materials and Methods: This was a prospective, randomized, open-label comparative study. Patients diagnosed with schizophrenia were randomly allocated into two treatment arms. One group (n = 50) was treated with olanzapine, and another group (n = 50) was treated with amisulpride. Patients were followed up for 12 weeks. Positive and negative syndrome scale score assessments were done to evaluate the efficacy parameter. Antipsychotic drug costs were also studied.

Results: In the treatment duration, it was observed that the positive and negative syndrome scores were 42.7% in the olanzapine-administered group, whereas the score was 33.8% in patients treated with amisulpride. The reduction in clinical global impression (CGI) score was 57% in the olanzapine group and 37% in the amisulpride group. The cost range for amisulpride was (Rs) 52.5–115.9 and for olanzapine was (Rs) 6.7–13.1 per positive and negative syndrome score improvement.

Conclusion: A significant decrease in positive and negative syndrome scores and CGI scores was evident in both groups treated with amisulpride and olanzapine, but olanzapine is more efficacious and cost-effective than amisulpride.

Key words: Efficacy; Cost Effectiveness; Amisulpride; Olanzapine; PANSS; Clinical Global Impression Scores

	ARTICLE TOOLS
	Abstract
	PDF Fulltext
	How to cite this article
	Citation Tools
	Related Records
	Articles by Chandrashekar Huded Articles by Harish G Bagewadi Articles by Prabhukiran Gogi Articles by Supriya Yedve
	on Google
	on Google Scholar

How to Cite this Article

Pubmed Style

Huded C, Bagewadi HG, Gogi P, Yedve S. A comparative study to assess the efficacy and cost-effectiveness of amisulpride versus olanzapine in schizophrenia patients at psychiatry outpatient department. Natl J Physiol Pharm Pharmacol. 2024; 14(9): 1971-1975. doi:10.5455/njppp.2024.14.10482202326042024

Web Style

Huded C, Bagewadi HG, Gogi P, Yedve S. A comparative study to assess the efficacy and cost-effectiveness of amisulpride versus olanzapine in schizophrenia patients at psychiatry outpatient department. https://www.njppp.com/?mno=172121 [Access: May 31, 2025]. doi:10.5455/njppp.2024.14.10482202326042024

AMA (American Medical Association) Style

Huded C, Bagewadi HG, Gogi P, Yedve S. A comparative study to assess the efficacy and cost-effectiveness of amisulpride versus olanzapine in schizophrenia patients at psychiatry outpatient department. Natl J Physiol Pharm Pharmacol. 2024; 14(9): 1971-1975. doi:10.5455/njppp.2024.14.10482202326042024

Vancouver/ICMJE Style

Huded C, Bagewadi HG, Gogi P, Yedve S. A comparative study to assess the efficacy and cost-effectiveness of amisulpride versus olanzapine in schizophrenia patients at psychiatry outpatient department. Natl J Physiol Pharm Pharmacol. (2024), [cited May 31, 2025]; 14(9): 1971-1975. doi:10.5455/njppp.2024.14.10482202326042024

Harvard Style

Huded, C., Bagewadi, . H. G., Gogi, . P. & Yedve, . S. (2024) A comparative study to assess the efficacy and cost-effectiveness of amisulpride versus olanzapine in schizophrenia patients at psychiatry outpatient department. Natl J Physiol Pharm Pharmacol, 14 (9), 1971-1975. doi:10.5455/njppp.2024.14.10482202326042024

Turabian Style

Huded, Chandrashekar, Harish G Bagewadi, Prabhukiran Gogi, and Supriya Yedve. 2024. A comparative study to assess the efficacy and cost-effectiveness of amisulpride versus olanzapine in schizophrenia patients at psychiatry outpatient department. National Journal of Physiology, Pharmacy and Pharmacology, 14 (9), 1971-1975. doi:10.5455/njppp.2024.14.10482202326042024

Chicago Style

Huded, Chandrashekar, Harish G Bagewadi, Prabhukiran Gogi, and Supriya Yedve. "A comparative study to assess the efficacy and cost-effectiveness of amisulpride versus olanzapine in schizophrenia patients at psychiatry outpatient department." National Journal of Physiology, Pharmacy and Pharmacology 14 (2024), 1971-1975. doi:10.5455/njppp.2024.14.10482202326042024

MLA (The Modern Language Association) Style

Huded, Chandrashekar, Harish G Bagewadi, Prabhukiran Gogi, and Supriya Yedve. "A comparative study to assess the efficacy and cost-effectiveness of amisulpride versus olanzapine in schizophrenia patients at psychiatry outpatient department." National Journal of Physiology, Pharmacy and Pharmacology 14.9 (2024), 1971-1975. Print. doi:10.5455/njppp.2024.14.10482202326042024

APA (American Psychological Association) Style

Huded, C., Bagewadi, . H. G., Gogi, . P. & Yedve, . S. (2024) A comparative study to assess the efficacy and cost-effectiveness of amisulpride versus olanzapine in schizophrenia patients at psychiatry outpatient department. National Journal of Physiology, Pharmacy and Pharmacology, 14 (9), 1971-1975. doi:10.5455/njppp.2024.14.10482202326042024

About National Journal of Physiology, Pharmacy and Pharmacology

Contact Information

How to cite this article